Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Apogenix GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient must be willing and able to give informed consent to participate in the trial and to adhere to the procedures stated in the protocol
≥18 years of age
Patient is admitted to a hospital (max. 72 hours prior to randomization) due to COVID-19 and has a positive SARS-CoV-2 PCR test
Clinical symptoms indicative of moderate or severe illness (corresponding to score 5 or 6 on the WHO 10-point clinical progression scale) with COVID 19 prior to trial treatment
Patient agrees to not participate in another clinical trial from screening until day 56
You may not be if
Patient is moribund or has an estimated life expectancy \<1 month (e.g., terminal cancer, etc.)
Patient is anticipated to be discharged from hospital within 48 hours
Patient requires anti-inflammatory medicines beyond SoC (SoC are drugs that are approved for treatment of COVID-19 as well as medicines that have been recommended in treatment guidelines of national health authorities and/or professional organization)
Patient requires invasive mechanical ventilation
Patient is known to have active tuberculosis
Patient is known to have hereditary fructose intolerance.
Patient is known to have co-infection with Influenza viruses or other viral respiratory infections (respiratory syncytial virus \[RSV\], parainfluenza viruses, respiratory adenoviruses).
Clareo Health | Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease
